SCHEMBL14238

SCHEMBL14238

NC1CCN(Cc2ccc(-n3cc4cc(-c5ccc(S(=O)(=O)NC6CCNCC6)cc5F)[nH]c4nc3=O)cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 4/20 0.40
ADORA3 P0DMS8 3/20 0.40
ADORA1 P30542 3/20 0.40
CCR3 P51677 1/20 0.39
ALDH1A1 P00352 1/20 0.38
KMT2A Q03164 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TP53 P04637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KIT P10721 4/20 0.36
HTT P42858 1/20 0.35
THRB P10828 1/20 0.35
PDK1 Q15118 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK3 Q15120 1/20 0.35
PDK4 Q16654 1/20 0.35
KDR P35968 1/20 0.34
HTR6 P50406 2/20 0.34
HTR1A P08908 1/20 0.34
DRD2 P14416 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12062108 0.85 ADORA2B (0.44) ADORA2BADORA3ADORA1CCR3ALDH1A1
SCHEMBL14408 0.84 KIT (0.34) KMT2AKITKDR
SCHEMBL14209 0.84 KIT (0.34) ADORA2BADORA3ADORA1KMT2AKIT
SCHEMBL20082562 0.78 ADORA2B (0.42) ADORA2BADORA3ADORA1CCR3ALDH1A1
SCHEMBL12061522 0.78 KIT (0.31) KITKDR
SCHEMBL14326 0.78 KDR (0.34) KMT2AKITKDR
SCHEMBL14735 0.75 KIT (0.39) ADORA2BADORA3ADORA1KIT
SCHEMBL14078 0.74 KIT (0.38) ADORA2BADORA3ADORA1KIT
SCHEMBL20082365 0.74 ADORA2B (0.38) ADORA2BADORA3ADORA1CCR3ALDH1A1
SCHEMBL21368157 0.72 KIT (0.36) ADORA2BKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2488525-B1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MELINTA THERAPEUTICS INC (US) 2018-04-25 EP disclosed
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME BioVersys AG (CH) 2016-02-04 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-9193731-B2 Antimicrobial compounds and methods of making and using the same MELINTA THERAPEUTICS, INC. (US) 2015-11-24 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same RIB-X PHARMACEUTICALS, INC. (US) 2012-08-30 US disclosed
WO-2011047319-A2 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME RIB-X PHARMACEUTICALS, INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220566-A1 Antimicrobial Compounds and Methods of Making and Using the Same MPO, LPO, CAT ADORA2B 3920/4885ADORA3 3018/4885ADORA1 3151/4885
US-20160031893-A1 ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME MPO, LPO, CAT ADORA2B 3920/4885ADORA3 3018/4885ADORA1 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.